Oncoinvent (ONCIN) DNB Carnegie Nordic Healthcare Conference presentation summary

Disease background and unmet need

• Peritoneal carcinomatosis is a lethal, advanced cancer stage with poor prognosis and high recurrence rates, affecting over 1 million patients globally.

• Limited treatment options and high lethality drive significant unmet medical need, especially in ovarian and colorectal cancers.

• Ovarian cancer often presents with peritoneal metastasis, with up to 85% relapse after surgery and median survival of 6–36 months post-relapse.

Radspherin mechanism and clinical rationale

• Radspherin is an intraperitoneal alpha therapy using radium-224-laden microparticles, administered post-surgery to eradicate residual microscopic disease.

• Alpha radiation delivers potent, localized DNA damage, effective regardless of cancer cell type, with no known resistance mechanisms.

• The 3.6-day half-life of radium-224 ensures sustained local effect while minimizing harm to healthy tissue.

Clinical data and efficacy

• Phase 1 ovarian cancer data: 90% peritoneal recurrence-free at 24 months in highest dose group.

• Phase 1/2a colorectal cancer data: 72% peritoneal recurrence-free at 18 months in highest dose group.

• Radspherin shows lower recurrence rates compared to historical controls, with encouraging investigator feedback.